Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease

• Egile Nagusiak: Yaning Zheng (Egilea), Sheng Ma (Egilea), Qiaomu Huang (Egilea), Yu Fang (Egilea), Hongjin Tan (Egilea), Yong Chen (Egilea), Cairong Li (Egilea)
• Formatua: Liburua
• Argitaratua: Karger Publishers, 2022-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: The phase III clinical trial of the nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) has been completed, aiming to investigate renal and cardiovascular outcomes in type 2 diabetes (T2D) with chronic kidney disease (CKD). However, the efficacy and safety of fine...